AHK-Cu dosage: reported doses and schedule
A copper peptide used in scalp serums, with laboratory findings and weak patent-only human data.
Also called: Ala-His-Lys copper complex, L-alanyl-L-histidyl-L-lysine copper(II), Copper tripeptide-3.
Healing and repair peptides · Copper-bound tripeptide.
Typical reported dose: About 0.3 mL of a 1% serum on the scalp once a day
- Patent scalp mixture, 0.1%: AHK-Cu 1 mg/mL in the full Example 1 mixture; scalp volume unstated. once each evening, on the skin. Studied in a trial. Studied in: Participants in the cited patent experiment. (source)
- Patent eyelash formula, 0.2%: 0.20% AHK-Cu by weight; thin line of formula on one upper eyelid. nightly, on the skin. Studied in a trial. Studied in: Participants in the cited patent experiment. (source)
- Reported 1% scalp serum: 1% serum; one user reports about 0.3 mL/day. Nominally 3 mg/day if 1% means 10 mg/mL. once daily, on the skin. Reported by users, occasional report. Studied in: Adults reporting self-use. (source)
- Reported nightly dropper: 300 mg in a 30 mL serum bottle; 1–1.5 droppers nightly. Dropper volume unstated. nightly, on the skin. Reported by users, occasional report. Studied in: Adults reporting self-use. (source)
- Reported 50 mg scalp batch: 50 mg in 30 mL bacteriostatic water plus 0.5 g sodium hyaluronate; 1 mL daily. Author reports 1.66 mg/day. once daily, on the skin. Reported by users, rare report. Studied in: Adults reporting self-use. (source)
- Reported daily injections: One report started 2–3 mg/day, then used AHK-Cu 2 mg plus GHK-Cu 2 mg daily. daily, under the skin. Reported by users, rare report. Studied in: Adults reporting self-use. (source)
Highest studied: Highest identified human scalp concentration: 1 mg/mL in a patent mixture. Daily mg dose unstated..
These are doses reported in labels, trials or user reports, not a personal plan. Check the source behind each one.
Related to AHK-Cu
- BPC-157: An experimental repair peptide with mostly animal evidence and a few small human reports.
- TB-500: A short piece of thymosin beta-4 with no proven repair benefit in humans.
- GHK-Cu: A copper-binding skin peptide with small topical studies and untested systemic injections.
- Thymosin beta-4: A peptide studied for eye conditions and skin wounds; tendon-repair injections lack controlled human evidence.
- ARA-290: Experimental peptide studied for small-fiber nerve damage, with uncertain pain relief and safety.
- Ac-SDKP: An experimental repair peptide with old human studies, but no proven healing dose.
Sources
- 21 CFR 216.23 — Bulk drug substances that can be used to compound drug products in accordance with section 503A of the Federal Food, Drug, and Cosmetic Act., Office of the Federal Register · eCFR · 2026
- 503B Bulk Drug Substances List, FDA · FDA · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2026
- Medicines, European Medicines Agency · European Medicines Agency · 2026
- MHRA Products | Home, MHRA · MHRA · 2026
- The 2026 Prohibited List, World Anti-Doping Agency · WADA · 2026
- Therapeutic Goods (Poisons Standard—October 2026) Instrument 2026, Australian Government · 2026
- Bulk Drug Substances Nominated for Use in Compounding Under Section 503B of the Federal Food, Drug, and Cosmetic Act, FDA · FDA · 2025
- Allergens in Cosmetics, U.S. Food and Drug Administration · FDA
- Australian Register of Therapeutic Goods (ARTG), Therapeutic Goods Administration · TGA
- Drug Product Database: Access the database, Health Canada · Health Canada
- Drugs@FDA: FDA-Approved Drugs, FDA · FDA
- Eye Cosmetic Safety, US Government
- FYs 2013-2017 Regulatory Science Report: Complex Mixtures and Peptides, FDA · FDA
- Is It a Cosmetic, a Drug, or Both? (Or Is It Soap?), FDA
Sources checked: 2026-10-18.
Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.